# Nebulised Heparin to Reduce COVID-19 Induced Acute Lung Injury

> **NCT04511923** · PHASE1,PHASE2 · COMPLETED · sponsor: **University College Hospital Galway** · enrollment: 40 (actual)

## Conditions studied

- Covid19
- ARDS, Human
- Lung Injury, Acute
- Ventilation Perfusion Mismatch

## Interventions

- **DRUG:** Nebulised heparin

## Key facts

- **NCT ID:** NCT04511923
- **Lead sponsor:** University College Hospital Galway
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-23
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-02-28
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2024-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04511923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04511923, "Nebulised Heparin to Reduce COVID-19 Induced Acute Lung Injury". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04511923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*